Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
New EVA Application
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Publ. Version/Full Text
DOI
PMC
 |
Closed |
Open Access Green as soon as Postprint is submitted to ZB.
Reply to "Tolerogenic insulin peptide therapy precipitates type 1 diabetes".
J. Exp. Med. 214, 2157-2159 (2017)
In this issue of JEM, Bergman et al. (https://doi.org/10.1084/jem.20160471) challenge the data published in our previous JEM paper on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Here, we provide a response to these data and suggest that appropriate subimmunogenic conditions are required to induce Foxp3(+) regulatory T cell conversion.
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
1
1
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Letter to the Editor
Keywords
Nod Mouse; T-cells; In-vivo; Differentiation; Vaccination; Microbiota; Antigen; Mtor; Akt
Language
english
Publication Year
2017
HGF-reported in Year
2017
ISSN (print) / ISBN
0022-1007
e-ISSN
1540-9538
Journal
Journal of Experimental Medicine
Quellenangaben
Volume: 214,
Issue: 7,
Pages: 2157-2159
Publisher
Rockefeller University Press
Publishing Place
New York
Reviewing status
Peer reviewed
Institute(s)
Research Unit Type 1 Diabetes Immunology (TDI)
POF-Topic(s)
30201 - Metabolic Health
Research field(s)
Helmholtz Diabetes Center
PSP Element(s)
G-502191-001
WOS ID
WOS:000404561900022
Scopus ID
85021886112
PubMed ID
28536240
Erfassungsdatum
2017-07-12